Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154119140> ?p ?o ?g. }
- W3154119140 endingPage "1002" @default.
- W3154119140 startingPage "989" @default.
- W3154119140 abstract "Intravenous and subcutaneous hypomethylating agents have held a key role in myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia treatment. Following the approval of the cedazuridine/decitabine combination, ASTX727, as well as development of an oral formulation of azacitidine, CC-486, in the USA in 2020, these agents could gradually replace their injectable counterparts.ASTX727 is approved for the treatment of adult patients with intermediate 1 or high-risk MDS as well as those with chronic myelomonocytic leukemia based on the findings from the ASTX727-01-B and ASCERTAIN trials. Oral azacitidine (CC-486) is approved for maintenance treatment of acute myeloid leukemia after induction chemotherapy for patients unfit for allogeneic hematopoietic cell transplant based on the findings from the QUAZAR AML-001 trial.Oral hypomethylating agent formulations have the potential to offer a convenient alternative to injectable hypomethylating agent. However, their current FDA-approved indications are narrow and efficacy needs to be shown in clinical trials before considering use beyond the approved indications. Areas of special interest include: identification of predictive biomarkers for clinical benefit, post-transplant maintenance therapy, and potential combination therapies with other oral agents such as venetoclax, IDH and FLT3 inhibitors." @default.
- W3154119140 created "2021-04-26" @default.
- W3154119140 creator A5042349927 @default.
- W3154119140 creator A5060316201 @default.
- W3154119140 creator A5062331658 @default.
- W3154119140 creator A5067521829 @default.
- W3154119140 creator A5068410542 @default.
- W3154119140 creator A5084588977 @default.
- W3154119140 date "2021-04-28" @default.
- W3154119140 modified "2023-09-23" @default.
- W3154119140 title "The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era" @default.
- W3154119140 cites W1119150976 @default.
- W3154119140 cites W1558398160 @default.
- W3154119140 cites W1600365609 @default.
- W3154119140 cites W1615743071 @default.
- W3154119140 cites W1804224861 @default.
- W3154119140 cites W1975352630 @default.
- W3154119140 cites W1975522050 @default.
- W3154119140 cites W1993236149 @default.
- W3154119140 cites W2003081290 @default.
- W3154119140 cites W2005289703 @default.
- W3154119140 cites W2078294866 @default.
- W3154119140 cites W2081279521 @default.
- W3154119140 cites W2095342617 @default.
- W3154119140 cites W2098298980 @default.
- W3154119140 cites W2099196272 @default.
- W3154119140 cites W2106082819 @default.
- W3154119140 cites W2106084333 @default.
- W3154119140 cites W2106584820 @default.
- W3154119140 cites W2113099773 @default.
- W3154119140 cites W2118771330 @default.
- W3154119140 cites W2148428508 @default.
- W3154119140 cites W2157287007 @default.
- W3154119140 cites W2159738043 @default.
- W3154119140 cites W2160968219 @default.
- W3154119140 cites W2162700652 @default.
- W3154119140 cites W2168473428 @default.
- W3154119140 cites W2169007954 @default.
- W3154119140 cites W2198196477 @default.
- W3154119140 cites W2260812679 @default.
- W3154119140 cites W2265091238 @default.
- W3154119140 cites W2298831567 @default.
- W3154119140 cites W2312226365 @default.
- W3154119140 cites W2339658711 @default.
- W3154119140 cites W2346463552 @default.
- W3154119140 cites W2419140434 @default.
- W3154119140 cites W2543307778 @default.
- W3154119140 cites W2549790759 @default.
- W3154119140 cites W2557522838 @default.
- W3154119140 cites W2558115358 @default.
- W3154119140 cites W2559398122 @default.
- W3154119140 cites W2559537906 @default.
- W3154119140 cites W2572742978 @default.
- W3154119140 cites W2583644779 @default.
- W3154119140 cites W2596295815 @default.
- W3154119140 cites W2617432132 @default.
- W3154119140 cites W2751645476 @default.
- W3154119140 cites W2772063923 @default.
- W3154119140 cites W2808807711 @default.
- W3154119140 cites W2884246240 @default.
- W3154119140 cites W2885331395 @default.
- W3154119140 cites W2891905200 @default.
- W3154119140 cites W2898284215 @default.
- W3154119140 cites W2901332394 @default.
- W3154119140 cites W2904142799 @default.
- W3154119140 cites W2923645205 @default.
- W3154119140 cites W2950620394 @default.
- W3154119140 cites W2978737808 @default.
- W3154119140 cites W2979538951 @default.
- W3154119140 cites W2984346248 @default.
- W3154119140 cites W2986575254 @default.
- W3154119140 cites W2989764345 @default.
- W3154119140 cites W2998901800 @default.
- W3154119140 cites W3000605006 @default.
- W3154119140 cites W3015984203 @default.
- W3154119140 cites W3032324849 @default.
- W3154119140 cites W3033279033 @default.
- W3154119140 cites W3037802405 @default.
- W3154119140 cites W3048827006 @default.
- W3154119140 cites W3096338919 @default.
- W3154119140 cites W3096717709 @default.
- W3154119140 cites W3097908641 @default.
- W3154119140 cites W3101738346 @default.
- W3154119140 cites W3102664424 @default.
- W3154119140 cites W3114952208 @default.
- W3154119140 cites W606465697 @default.
- W3154119140 doi "https://doi.org/10.1080/14737140.2021.1918002" @default.
- W3154119140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33853476" @default.
- W3154119140 hasPublicationYear "2021" @default.
- W3154119140 type Work @default.
- W3154119140 sameAs 3154119140 @default.
- W3154119140 citedByCount "2" @default.
- W3154119140 countsByYear W31541191402021 @default.
- W3154119140 countsByYear W31541191402022 @default.
- W3154119140 crossrefType "journal-article" @default.
- W3154119140 hasAuthorship W3154119140A5042349927 @default.
- W3154119140 hasAuthorship W3154119140A5060316201 @default.
- W3154119140 hasAuthorship W3154119140A5062331658 @default.